ProCE Banner Activity

RATIONALE-315: Surgical Outcomes From Phase III Trial of Perioperative Tislelizumab, a PD-1 Inhibitor, Plus Neoadjuvant Chemotherapy in Resectable NSCLC

Conference Coverage

In this analysis of surgical outcomes from the phase III RATIONALE-315 trial, adding the PD-1 inhibitor tislelizumab to neoadjuvant chemotherapy did not affect surgical feasibility or completeness vs adding placebo to neoadjuvant chemotherapy in Chinese patients with resectable stage II-IIIA NSCLC.

Released: May 16, 2024

Expiration: May 15, 2025


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc